← Back to directory

Nicholas J. Ashton

Researcher Next ID · RN-021687

Researcher · Medicine

Alzheimer's Association

Chicago, Norway

Not currently recruitingFunding unknown
Works count
687
Citation count
30,324
H-index
91
i10-index
334

Research interests

Medicine
Neuroscience
Biochemistry, Genetics and Molecular Biology
Alzheimer's disease research and treatments
Dementia and Cognitive Impairment Research
Neuroinflammation and Neurodegeneration Mechanisms
Neurological Disease Mechanisms and Treatments
S100 Proteins and Annexins

Publications

  • Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

    JAMA Neurology · 2024 · https://doi.org/10.1001/jamaneurol.2023.5319

  • Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease

    Nature Medicine · 2023 · 10.1038/s41591-023-02380-x

  • A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

    Nature Aging · 2023 · 10.1038/s43587-023-00471-5

  • Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

    JAMA Neurology · 2023 · 10.1001/jamaneurol.2022.5272

  • Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility

    Nature Reviews Neurology · 2022 · 10.1038/s41582-022-00665-2

  • Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

    Brain · 2022 · https://doi.org/10.1093/brain/awac333

  • Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

    Nature Medicine · 2022 · 10.1038/s41591-022-02074-w

  • Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

    Nature Medicine · 2022 · 10.1038/s41591-022-01925-w

  • Biomarker modeling of Alzheimer’s disease using PET-based Braak staging

    Nature Aging · 2022 · 10.1038/s43587-022-00204-0

  • Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography

    JAMA Neurology · 2022 · 10.1001/jamaneurol.2022.4485

  • Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration

    Brain · 2022 · 10.1093/brain/awac407

  • The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

    Alzheimer s & Dementia · 2021 · 10.1002/alz.12283

  • Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

    JAMA Neurology · 2021 · 10.1001/jamaneurol.2020.4986

  • A multicentre validation study of the diagnostic value of plasma neurofilament light

    Nature Communications · 2021 · https://doi.org/10.1038/s41467-021-23620-z

  • Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

    JAMA Neurology · 2021 · https://doi.org/10.1001/jamaneurol.2021.3671

  • Microglial activation and tau propagate jointly across Braak stages

    Nature Medicine · 2021 · 10.1038/s41591-021-01456-w

  • Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

    JAMA Neurology · 2021 · 10.1001/jamaneurol.2021.2293

  • Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease

    Alzheimer s & Dementia · 2021 · 10.1002/alz.12447

  • Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

    Brain · 2021 · https://doi.org/10.1093/brain/awab223

  • Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

    The Lancet Neurology · 2020 · 10.1016/s1474-4422(20)30071-5

  • Steroid‐Responsive Encephalitis in Coronavirus Disease 2019

    Annals of Neurology · 2020 · 10.1002/ana.25783

  • Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

    Brain · 2020 · 10.1093/brain/awaa399

  • Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

    Neurology · 2020 · 10.1212/wnl.0000000000010111

  • Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

    Molecular Psychiatry · 2020 · 10.1038/s41380-020-00923-z

  • Role of Oxygen in the Genesis of Retrolental Fibroplasia: A Preliminary Report

    British Journal of Ophthalmology · 1953 · 10.1136/bjo.37.9.513

Current projects

    No projects listed.